Approval of new biomedical sealants in key regions such as Europe is expected to drive growth of
the biomedical sealant market. For instance, in 2017, Starch Medical, marketer and manufacturer of
polysaccharide-based hemostatic products such as biomedical sealants was approved by C.E. Mark
for Super Clot. Post the approval, company has planned to utilize their existing network of
distribution partners along with their new strategic partners to bring Super Clot to hospitals and
surgical teams throughout Europe. This strategic planning of product distribution is expected to fuel
growth of the global biomedical sealant market.
Mergers and acquisitions by key players is also another factor expected to support the global
biomedical sealant market growth. For instance, in January 2018, Baxter International Inc., a U.S.-
based healthcare company, acquired two surgical products i.e. Recothrom and Preveleak of
Mallinckrodt Pharmaceuticals—a producer of specialty pharmaceutical products. Recothrom is a
thrombin based topical product, which is designed to assist hemostasis, this product is used when
surgical methods to prevent flow of blood is ineffective in adults and pediatrics. Preveleak is a
surgical sealant used to close suture holes to obtain hemostasis during surgical vascular
reconstructions.
Non-availability of one sealants, which provide stiffness, elasticity, and high adhesion together, is a
major restraining factor for growth of the market. For instance, though fibrin-based sealants do offer
good elasticity, these offer low stiffness and adhesion. Cyanoacrylates have high adhesion and
stiffness, however, offer low elasticity. These factors could negatively impact growth of the market
over the forecast period.
For More Information @
https://www.coherentmarketinsights.com/ongoing-insight/biomedical-sealant-market-1936
Biomedical Sealant Market Regional Analysis:-
North America is expected to be dominant in the global biomedical sealant market over the forecast
period. This is due to increasing product launches by key players in the region. For instance, in
2017, Starch Medical, a marketer and manufacturer of polysaccharide-based hemostatic products
such as biomedical sealants, launched its new product Super Clot. Super Clot is a biomedical
sealant used for effective and rapid hemostasis. Such new products in the market are expected to
boost growth of the North America biomedical sealant market.
Europe biomedical sealant market is also expected to exhibit significant growth over the forecast
period. This is due to increasing number of approvals for new products by Certification Marking
(C.E. Mark). For instance, in 2017, Gecko Medical, a medical device company which develops
innovative polymers to support reconstruction of tissue, announced C.E mark approval for its
product SETALUM sealant.
SETALUM sealant is bio-reabsorb able, biocompatible, and can also be used in dynamic and wet
environments such as blood as an add-on to sutures during vascular surgeries. This sealant is
applied to tissue in an appropriate position and is further activated using a light activation pen. This
sealant is easily applicable due to its viscosity and hydrophobicity..
Biomedical Sealant Market Key Players:-
Key players operating in the global biomedical sealant include Bostik, 3M Company, Henkel AG &
company, KGaA., CryoLife Inc., Chemence Ltd., Cyberbond LLC., Ethicon Inc., Covidien PLC.,
Glustitch Inc., Adhezion Biomedical LLC., Cohera Medical Inc., Baxter International Inc., Meyer
Haake GmbH, Angiotech Pharmaceuticals Inc., and Biocoral Inc.
Biomedical Sealant Market Taxonomy:-